These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 120169)

  • 1. Haemagglutination inhibition and aggregation of Fusobacterium nucleatum by human salivary mucinous glycoproteins.
    Falkler WA; Mongiello JR; Burger BW
    Arch Oral Biol; 1979; 24(7):483-9. PubMed ID: 120169
    [No Abstract]   [Full Text] [Related]  

  • 2. Sugar inhibition of oral Fusobacterium nucleatum haemagglutination and cell binding.
    Mongiello JR; Falkler WA
    Arch Oral Biol; 1979; 24(7):539-45. PubMed ID: 44185
    [No Abstract]   [Full Text] [Related]  

  • 3. Attachment of serum non-antibody glycoproteins to the Fusobacterium nucleatum found in periodontal disease.
    Smoot CN; Falkler WA
    Arch Oral Biol; 1981; 26(11):859-64. PubMed ID: 6950701
    [No Abstract]   [Full Text] [Related]  

  • 4. Human salivary aggregation in Streptococcus intermedius type g strains: relationship with IgA.
    Yamaguchi T
    FEMS Immunol Med Microbiol; 2004 Jun; 41(2):101-7. PubMed ID: 15145453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-antigenic cross-reactivity in Fusobacterium nucleatum.
    Hofstad T; Skaug N; Bjørnland T
    Acta Pathol Microbiol Scand B; 1979 Dec; 87(6):371-4. PubMed ID: 94236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral priming followed by parenteral immunization with HIV-immunosomes induce HIV-1-specific salivary and circulatory IgA in mice and rabbits.
    Thibodeau L; Tremblay C; Lachapelle L
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1379. PubMed ID: 1466960
    [No Abstract]   [Full Text] [Related]  

  • 7. Titration of inhibiting antibodies to bacterial IgA1 proteases in human sera and secretions.
    Reinholdt J; Kilian M
    Adv Exp Med Biol; 1995; 371A():605-8. PubMed ID: 8525999
    [No Abstract]   [Full Text] [Related]  

  • 8. O-antigenic corss-reactivity in Fusobacterium nucleatum: chemotype V lipopolysaccharides.
    Adnegard B; Horstad T
    Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):93-5. PubMed ID: 6191518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding specificity of Fusobacterium nucleatum to human erythrocytes, polymorphonuclear leukocytes, fibroblasts, and HeLa cells.
    Ozaki M; Miyake Y; Shirakawa M; Takemoto T; Okamoto H; Suginaka H
    J Periodontal Res; 1990 May; 25(3):129-34. PubMed ID: 2141873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Streptococcus crista and human saliva on the viability of Fusobacterium nucleatum ATCC 10953.
    Rudney JD; Strait CA
    Arch Oral Biol; 2000 Aug; 45(8):667-74. PubMed ID: 10869478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of divalent cation chelators and magnesium on activation of the alternative complement pathway by Fusobacterium polymorphum (nucleatum).
    Hawley CE; Falkler WA
    J Periodontal Res; 1979 Sep; 14(5):390-6. PubMed ID: 161780
    [No Abstract]   [Full Text] [Related]  

  • 12. Salivary specific antibodies in relation to adhesion of Streptococcus pyogenes to pharyngeal cells of patients with rheumatic fever and rheumatic heart disease.
    Kumar KS; Ganguly NK; Chandrashekher Y; Anand IS; Wahi PL
    Adv Exp Med Biol; 1995; 371A():677-9. PubMed ID: 8526017
    [No Abstract]   [Full Text] [Related]  

  • 13. [Salivary immunoglobulins in chronic recurrent aphthae of the oral mucosa].
    Zółtowska A; Witek E; Góra B; Romankiewicz-Wózniczko G
    Czas Stomatol; 1985 Apr; 38(4):291-6. PubMed ID: 3867449
    [No Abstract]   [Full Text] [Related]  

  • 14. Salivary immunoglobulin A directed to oral microbial GroEL in patients with periodontitis and their potential protective role.
    Fukui M; Hinode D; Yokoyama M; Tanabe S; Yoshioka M
    Oral Microbiol Immunol; 2006 Oct; 21(5):289-95. PubMed ID: 16922927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Helicobacter pylori haemagglutination activity by human salivary mucins.
    Mentis A; Tzouvelekis L; Spiliadis C; Blackwell CC; Weir DM
    FEMS Microbiol Immunol; 1990 Oct; 2(3):125-7. PubMed ID: 2257167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth of oral bacteria on saliva.
    De Jong MH; Van der Hoeven JS
    J Dent Res; 1987 Feb; 66(2):498-505. PubMed ID: 3305628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial potential of saliva in children with leukemia.
    Karolewska E; Konopka T; Pupek M; Chybicka A; Mendak M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun; 105(6):739-44. PubMed ID: 18329914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ontogeny and senescence of salivary immunity.
    Smith DJ; Taubman MA; Ebersole JL
    J Dent Res; 1987 Feb; 66(2):451-6. PubMed ID: 3040823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One year in Antarctica: mucosal immunity at three Australian stations.
    Gleeson M; Francis JL; Lugg DJ; Clancy RL; Ayton JM; Reynolds JA; McConnell CA
    Immunol Cell Biol; 2000 Dec; 78(6):616-22. PubMed ID: 11114972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Saliva as a main component of oral cavity ecosystem. Part II. Defense mechanisms].
    Jankowska AK; Waszkiel D; Kobus A; Zwierz K
    Wiad Lek; 2007; 60(5-6):253-7. PubMed ID: 17966890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.